Linda Duska

[Moffitt Cancer Center @MoffittNews]

During the #SGOMtg, Linda Duska, MD (@LDuska) from @uvamedicine shares encouraging insights into the overall survival and progression-free survival results from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study based on the second interim analysis.

#MoffittSGO25 #SGO2025 #SGOAM2025 #MultipleYourImpact #CancerResearch #CervicalCancer

[OncLive.com @OncLive]

Our first interview of the day was with @LDuska of @uvamedicine, who shared key OS and PFS2 data from the second interim analysis of the KEYNOTE-A18 study. Hear a brief preview of her research below, and check out https://t.co/E5LOd0oQIM for more details! @SGO_org #SGOMtg #gynsm

[SGO @SGO_org]

The SGO released a clinical practice advisory addressing the nationwide shortage of intravenous (IV) solutions. These guidelines outline strategy considerations to manage the shortage in various settings while maintaining high-quality patient care.

https://t.co/tyBQilySSK

[Angeles Secord @AngelesSecord]

Dr Eskander - Beware of Harkening #IGCS2024 @SGO_org @GOG Important to interpret post hoc analyses with caution

[Angeles Secord @AngelesSecord]

Wow Drop the mic moment Dr Ramez!!!! Review of DUO-E and KN-B21

[Angeles Secord @AngelesSecord]

KN-B21 dMMR cohort highly positive 👍🤩🥰#IGCS2024 @SGO_org @GOG

[Angeles Secord @AngelesSecord]

KN-B21 subgroup analysis of dMMR cohort - highly anticipated! #IGCS2024 @SGO_org @GOG

[Angeles Secord @AngelesSecord]

Dr Westin present post hoc DUO-E exploratory analysis of biomarkers- high degree of heterogeneity with significant overlap. #IGCS2024 @SGO_org @GOG

[Susan Zweizig @SusanZweizig]

#IGCS 2024 Thoughtful, excellent distillation by Dr Ramez Eskander on role of IO in endometrial cancer including the unknown, encourages care in interpreting data @SGO_org @UMassChan

[rcoledude @rcoledude]

Congratulations Shannon on updated results on DUO-E at #igcs2024

[Angeles Secord @AngelesSecord]

Dr Noelle Cloven - reassuring QoL data for patients on RUBY trial - the trifecta- improved PFS, OS, and QoL. #IGCS2024 @SGO_org @GOG

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

🎉A clear win at #IGCS2024!! Cadonilimab added to chemotherapy yielded improved improved progression free and overall in recurrent #cervicalcancer #gyncsm

[Angeles Secord @AngelesSecord]

Exciting poster presentations - video with Dr Brown capturing her thoughts on the BOUQUET trial 💐❤️💐

[Angeles Secord @AngelesSecord]

Dr Jubilee Brown presents BOUQUET data at #IGCS2024 @SGO_org @GOG
Rare tumors are important to study and yes - clinical trials are feasible. Love the biomarker data ❤️

[Debra Richardson, M.D. @DebbieRic23]

FIH SHR A1921 ADC targets tropical 2. Dose optimization in ovarian cancer 3mg/kg and 2mg/kg cohorts. Exciting response rate and PFS- 7.9 months 3mg/kg and 6.9 mg/kg for the 2mg/kg. Stomatitis common. @SGO_org @myESMO #ESMO2024

[Debra Richardson, M.D. @DebbieRic23]

A18 show OS benefit for addition of pembrolizumab to chemort in cervical cancer. HR 0.67. @SGO_org @myESMO #ESMO2024

[Floor Backes @FBackesMD]

avelumab + MTX was suggested as the new standard regimen for low risk GTD. Exciting >95% durable cure rate in stage 1-3, WHO score 1-6. @myESMO @SGO_org #esmo2024

[Debra Richardson, M.D. @DebbieRic23]

ATHENA- combo is negative. The addition of nivolumab to rucaparib was not better than rucaparib maintenance alone. The combo was more toxic. @SGO_org @myESMO

[Angeles Secord @AngelesSecord]

Congratulations Dr Westin and all DUO-E investigator!! Provocative data regarding combination durva + olaparib in patients with endometrial cancer - role of biomarkers??to direct combination vs IO only maintenance therapy. Impressive PFS!

[Angeles Secord @AngelesSecord]

What’s Happening at ESMO!!It was my honor and pleasure to sit down with Dr. Shannon Westin and talk about DUO- E. Check out this video from your friendly SGO reporter @SGO_org @GOG #ESMO23